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We describe the concordance among results from various laboratory tests using samples derived from nine
culture-proven cases of human monocytic ehrlichiosis (HME) caused by Ehrlichia chaffeensis. A class-specific
indirect immunofluorescence assay for immunoglobulin M (IgM) and IgG, using E. chaffeensis antigen,
identified 44 and 33% of the isolation-confirmed HME patients on the basis of samples obtained at initial
clinical presentation, respectively; detection of morulae in blood smears was similarly insensitive (22% posi-
tive). PCR amplifications of ehrlichial DNA targeting the 16S rRNA gene, the variable-length PCR target gene,
and the groESL operon were positive for whole blood specimens obtained from all patients at initial presen-
tation. As most case definitions of HME require a serologic response with compatible illness for a categori-
zation of even probable disease, PCR would have been required to confirm the diagnosis of HME in all nine
of these patients without the submission of a convalescent-phase serum sample. These data suggest that many,
if not most, cases of HME in patients who present early in the course of the disease may be missed and
underscore the limitations of serologically based surveillance systems.
Since the first isolation of Ehrlichia chaffeensis in cell culture
in 1990 (5), only three additional isolates had been recovered
by 1997 (14). The most common impediments to obtaining
isolates of E. chaffeensis have been ascribed to the fastidious
nature of the organism or to problems in obtaining whole
blood samples from acutely ill persons prior to the initiation of
antibiotic therapy. Disease caused by this tick-borne pathogen
is not commonly reported; however, more than 300 cases of
serologically confirmed human monocytic ehrlichiosis (HME)
have been identified through testing of paired acute- and con-
valescent-phase specimens submitted to the Centers for Dis-
ease Control and Prevention (CDC) since 1986 (2a).
Increasingly, cases of HME and human granulocytic ehrli-
chiosis (HGE) are being identified through mandated report-
ing programs initiated by state health departments. The case
definitions adopted by the Council of State and Territorial
Epidemiologists for the surveillance of the human ehrlichioses
include categories of “probable” disease (compatible illness
with a single serum sample that tests positive above a certain
minimum endpoint antibody titer) and “confirmed” disease
(compatible illness with a fourfold-or-greater change in anti-
body titer between paired acute- and convalescent-phase se-
rum specimens) (2). Other laboratory criteria that provide
confirmation of HME or HGE are the presence of membrane-
bound, intracytoplasmic bacterial aggregates (morulae) in
blood, cerebrospinal fluid, or bone marrow, concomitant with
a single positive serum sample, and the detection of specific
ehrlichial DNA sequences after DNA extraction of patient
tissue and PCR amplification by using specific primers for E.
chaffeensis or the HGE agent. The latter two confirmatory tests
are not universally available at state health laboratories and
require special expertise in their routine application and inter-
pretation.
Because the diagnosis of HME depends primarily on labo-
ratory methods designed to detect the patients’ immune re-
sponse to the pathogen or the presence of ehrlichial DNA, it is
essential to establish the concordance among various test re-
sults when using samples derived from culture-proven cases.
As with any cultivable pathogen, culture confirmation of E.
chaffeensis infection must be regarded the “gold standard” for
defining the parameters of other diagnostic tests. In this report,
we summarize the laboratory findings from nine patients with
culture-confirmed HME. The findings from this case series
underscore the limitations of serologically based surveillance
systems and suggest that a secondary level of testing is required
to identify the majority of HME cases when only a single
acute-phase blood specimen is available for testing.
MATERIALS AND METHODS
Patient samples. Whole blood samples were submitted to CDC by physicians
who treat patients with suspected HME. Six isolates of E. chaffeensis were
obtained from samples submitted to CDC during 1997 and 1998. Serum or
plasma specimens were available from each HME patient for acute-phase anti-
body titer determinations, and a second serum sample was obtained from five of
six patients. Isolates of E. chaffeensis were also obtained from three patients who
presented with suspected HME at Vanderbilt University, Nashville, Tenn. Coded
samples of whole blood specimens yielding these isolates were frozen at 280°C
until being forwarded to CDC along with three pairs of EDTA-anticoagulated
blood samples from non-HME patients. Paired acute- and convalescent-phase
sera were available from these three patients. Cell culture growth characteristics
and limited genetic sequence comparisons of two of the E. chaffeensis isolates
have been reported previously (14), as have detailed comparisons of variable-
length PCR target (VLPT) gene sequences for six of the isolates (18).
Isolation of E. chaffeensis. Aliquots of EDTA-anticoagulated whole blood were
diluted with 2 volumes of Hanks’ balanced salt solution and layered onto Hist-
paque 1083 (Sigma Diagnostics, St. Louis, Mo.). Following centrifugation at
800 3 g for 20 min, the pelleted cells were resuspended and placed in 25-cm2
flasks containing a semiconfluent layer of DH82 cells, as described in detail
previously (14). Inocula were removed after 24 h, and fresh culture medium was
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added to the flasks, after which cultures were monitored for evidence of ehrli-
chial infection by using cytocentrifuged preparations stained with Diff-Quik.
IFA testing. Serum or plasma samples were tested in class-specific assays using
the Arkansas isolate of E. chaffeensis as the antigen. The test details were as
previously described (13) for the HGE agent and E. chaffeensis testing. To
minimize variation, all samples were tested together by using the same lots of
antigen slides, conjugates, and other reagents.
The assay for immunoglobulin M (IgM) determinations followed the general
indirect immunofluorescence assay (IFA) protocol, but pretreatment of each
sample was included to remove interference from rheumatoid factors and spe-
cific IgG. Prior to assay using fluorescein isothiocyanate-labeled conjugate to
human IgM (m chain specific) at a 1/100 dilution (Kirkegaard & Perry Labora-
tories, Gaithersburg, Md.), 50-ml serum samples were depleted of IgG by using
a recombinant protein G affinity method (Quik-Sep IgM; Isolab, Inc., Akron,
Ohio). For the reciprocal endpoint titers of each assay, see below and Table 1.
Geometric mean titers (GMT) were calculated for reactive samples with IgM
titers of $16 and IgG titers of $64.
Extraction of DNA from blood samples and cultured cells. DNA was extracted
from 200 ml of patient whole blood by using the QIAmp Blood Kit (Qiagen Inc.,
Santa Clarita, Calif.) in accordance with the manufacturer’s recommendations.
PCR analyses of whole blood. PCR assays targeting three different genes were
used to detect and distinguish ehrlichial DNA. As these samples were initially
processed for diagnostic evaluation in separate laboratories, each of these assays
was performed independently and different DNA extractions were used for the
16S rRNA gene (rDNA) assays than for the VLPT and groESL operon assays.
Therefore, the analytic sensitivities of the various assays could not be compared
and were not assessed (17).
(i) 16S rDNA (primary and nested). The 16S rDNA was amplified by using
direct (single-step) and heminested protocols. The direct assay used primers
HE1 and HE3 and has already been described in detail (1). The heminested
assay consisted of a 50-ml primary reaction mixture containing 5 ml of the purified
DNA as the template and primers HE1 (1) and HE20 (59 GAATTCCGCTAT
CCTCTTTCGAC). All reagents were from the GeneAmp PCR Kit with Am-
pliTaq DNA Polymerase (Perkin-Elmer, Foster City, Calif.), and reactions were
performed in a Perkin-Elmer 9600 thermal cycler. Each primary PCR amplifi-
cation mixture contained 200 mM each deoxynucleoside triphosphate (dATP,
dCTP, dGTP, and dTTP), 1.25 U of Taq polymerase, and 0.5 mM each primer.
Cycling conditions involved an initial 2-min denaturation at 95°C and 40 cycles
each consisting of a 30-s denaturation at 94°C, 30 s of annealing at 55°C, and a
1-min extension at 72°C. These 40 cycles were followed by a 5-min extension at
72°C. Reaction products were subsequently maintained at 4°C until analyzed by
agarose gel electrophoresis or used as templates for nested reactions.
Heminested PCRs used 1 ml of the primary PCR product as the template.
Each nested amplification contained 200 mM each deoxynucleoside triphosphate
(dATP, dCTP, dGTP, and dTTP), 1.25 U of Taq polymerase, and primers HE1
and HE3 at 0.2 mM each in a total reaction volume of 50 ml. Nested cycling
conditions were identical to those of the primary amplification, except that only
30 cycles were used.
(ii) VLPT. The VLPT is a repetitive-motif sequence that varies in the number
of repeats among different isolates of E. chaffeensis (14). The number of repeats
was determined for each whole blood sample and the corresponding E. chaffeen-
sis isolate as an independent marker of the uniqueness of each isolate. The PCR
method and primers used for amplification of the VLPT from blood samples
originally submitted to CDC have been described previously in detail (18).
Patient whole blood samples from which cell culture isolations were made at
Vanderbilt University were tested at CDC to help assess interlaboratory consis-
tency. The standard VLPT primers were used (14), but the originally described
methods were changed by using Ready-To-Go PCR Beads in 0.2-ml tubes (Am-
ersham Pharmacia Biotech, Piscataway, N.J.) and a different thermocycler, the
Perkin-Elmer GenAmp 9600. For each 25-ml reaction mixture, individual beads
were dissolved in 23 ml of water containing primers FB5A and FB3A (each at a
concentration of 1 mM) to which 2 ml of the appropriate DNA extraction was
added. Thermocycler parameters were 94°C for 2 min, followed by 40 cycles
consisting of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min and then extention
at 72°C for 7 min. PCR products were separated by agarose gel electrophoresis,
stained with ethidium bromide, and visualized by UV illumination.
(iii) groESL operon. Primers HS1 and HS6 (primary reaction) and primers
HS43 and HS45 (nested reaction) were used to amplify a 528-bp segment of the
groESL heat shock operon from patient blood samples corresponding to the
Osceola, Liberty, West Paces, and Wakulla isolates of E. chaffeensis by methods
described in detail elsewhere (18). The same protocol was used for blood sam-
ples corresponding to the Jax and St. Vincent isolates, except that primer HS79
was substituted for primer HS43 to amplify a larger segment (1,302 bp) for
nucleotide sequencing (14). As with the VLPT PCR, the blood samples from
Vanderbilt University were tested by using Ready-To-Go PCR Beads and a
Perkin-Elmer GenAmp 9600. Cycling parameters for primary and nested reac-
tions were identical to those listed for the VLPT, except that the annealing
temperature for the groESL PCR primary reaction (primers HS1 and HS6) was
changed to 50°C.
Confirmation of PCR products. Purified PCR preparations from the VLPT
reactions of samples originally obtained at CDC were sequenced by using the
Prism Ready DyeDeoxy Cycle Sequencing kit (Applied Biosystems) as previously
described (18, 19). Both strands were sequenced by using an Applied Biosystems
370A or 377 automated sequencer.
RESULTS
Whole blood specimens from nine clinically ill patients with
a diagnosis of suspected HME were collected a median of 3
(range, 3 to 7) days after the initial onset of illness (Table 1).
Morulae were noted in the stained peripheral blood smears
from two of the nine patients. Four of the nine patients had a
class-specific IgM antibody titer to E. chaffeensis at the time of
initial clinical evaluation that would have been considered of
diagnostic relevance with the IFA (GMT, 22; range, 16 to 64);
three endpoint titers were at the minimum value tested, i.e., 16.
Three of the nine patients had detectable titers of IgG anti-
TABLE 1. Results of diagnostic testing by thin smear, class-specific IFA serology, and amplification of three different gene targets by PCRa
for nine isolation-confirmed HME cases caused by E. chaffeensis
Patient no./isolate Presence ofmorulaeb
IFA titerc PCR target gene result
First serum sample Second serum sample
16S rRNA VLPT(no. of repeats)
groESL
operonIgM
(days postonset) IgG
IgM
(days postonset) IgG
1/Jax 2 16 (7) 256 32 (13) 1,024 1 1 (4) 1
2/St. Vincent 1 ,16 (4) ,64 ,16 (8) ,64 1 1 (3) 1
3/Osceola 1 16 (3) ,64 64 (9) 1,024 1 1 (4) 1
4/Wakulla 2 ,16 (5) 512 256 (41) 2,048 1 1 (6) 1
5/Liberty 2 64 (3) 64 NTf NT 1 1 (4) 1
6/West Paces 2 ,16 (3) ,64 64 (51) 512 1d 1 (3) NT
7/V5e 2 ,16 (3) ,64 512 (43) 8,192 1 1 (4) 1
8/V6e 2 16 (3) ,64 512 (50) 2,048 1 1 (4) 1
9/V7e 2 ,16 (4) ,64 128 (53) 256 1 1 (5) 1
No. positive/total (%) 2/9 (22.2) 4/9 (44.4) 3/9 (33.3) 7/8 (87.5) 7/8 (87.5) 9/9 (100) 9/9 (100) 8/8 (100)
a 16S rDNA was amplified by nested PCR, as required for patients 5 and 6.
b Intracytoplasmic aggregates of bacteria observed in peripheral blood smears.
c IFA titers for IgM of $16 and for IgG of $64 are considered evidence of current or past infection with E. chaffeensis.
d Detected by heminested assay.
e Isolates designated V5 to V7 were obtained at Vanderbilt University, although additional testing of whole blood and sera was conducted at CDC.
f NT, not tested.
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body to E. chaffeensis at the time of their initial clinical eval-
uation that would have been considered of diagnostic rele-
vance with the IFA (GMT, 204; range, 64 to 512); one
endpoint titer was equal to the minimum value considered
significant in this study, i.e., 64.
Of the eight patients from whom a second serum sample was
collected at a median of 42 (range, 8 to 53) days postonset, four
additional patients developed IgM titers of $16, bringing the
number of patients with detectable IgM to seven of eight
(GMT, 141; range, 32 to 512). The three patients with initial
IgM titers of 16, for whom second samples were available,
showed titer increases to 32, 256, and 512 (Table 1). Five
patients demonstrated class-specific IgG seroconversion to E.
chaffeensis antigen from initial titers of ,64 to titers ranging
from 128 to 4,096 (Table 1). Two patients with IgG antibody
titers of $64 at initial presentation had greater-than-fourfold
increases in their endpoint titers at the second sampling, 6 and
36 days after their first blood samples were drawn (patients 1
and 4; Table 1). Overall, the number of patients with detect-
able IgG at either the first or second testing of sera was eight
of nine. The IgG class-specific GMT for the seven patients with
positive second serum samples was 1,261 (range, 256 to 8,192).
One patient concomitantly infected with the human immuno-
deficiency virus (patient 2; Table 1) had IgM titers of ,16 and
IgG titers of ,64 at days 4 and 8 after onset of illness, at which
time he died of HME.
EDTA-anticoagulated whole blood samples obtained at the
time of initial presentation and leading to the isolation of E.
chaffeensis were positive for ehrlichial DNA by PCR amplifi-
cation of regions of the 16S rDNA, the VLPT gene, and the
groESL operon for all patients (Table 1).
The number of repeat units present in the PCR amplicons of
the VLPT were identical when the results from whole blood
samples and E. chaffeensis isolates obtained in cell culture were
compared. Samples analyzed separately at Vanderbilt Univer-
sity and CDC gave identical results. None of the three paired
samples from non-HME cases submitted by Vanderbilt Uni-
versity was positive by any test.
DISCUSSION
The results reported here, although based on a small series
of HME patients, are a first attempt to compare diagnostic
outcomes from various laboratory tests by using specimens
obtained from patients with culture-confirmed E. chaffeensis
infection. These comparisons permitted a preliminary assess-
ment of different methods for inferring an infectious process
either through detection of antibody or through identification
of DNA from organisms of undetermined viability. The validity
of laboratory methods, such as serologic testing, in determin-
ing disease status early in infection is frequently assumed and
relied upon by the public health community interested in sur-
veilling for HME (8). The data reported here indicate that
early serologic testing by the most widely available test, an IFA
for IgM and IgG antibody detection using E. chaffeensis anti-
gen, missed 56 and 67% of the isolation-confirmed HME pa-
tients, respectively, at initial clinical presentation and first-
sample collection. Detection of morulae in blood smears
(22%) was also insensitive for HME diagnosis. As most case
definitions of HME require a serologic response with compat-
ible illness for categorization of even probable disease (2),
many, if not most, cases of HME in patients who present early
in the course of the disease may be missed. The significance of
these findings is corroborated by results from epidemiologic
studies of HME indicating that the median time from disease
onset to the first visit to a physician was 4 days (8), similar to
the 3-day interval described in this case series.
It is widely understood that initiation of antibiotic treatment
for potentially fatal tick-borne diseases, such as the ehrlichio-
ses or Rocky Mountain spotted fever (RMSF), rests on clinical
suspicion and not laboratory test results that may require
weeks to obtain (7, 10). As laboratory confirmation of the
diagnosis is not directly linked to initiation of treatment, ob-
taining second serum samples during convalescence, typically 3
to 6 weeks after onset of disease, may become a low priority for
physicians. However, case definitions for the confirmation of a
diagnosis of a tick-borne rickettsial disease, promulgated by
the Council of State and Territorial Epidemiologists and CDC
and in use by many states, require testing of paired serologic
specimens to demonstrate a fourfold-or-greater change in an-
tibody titer. Although seven of the eight patients for whom
paired samples were available seroconverted by IgG or IgM
with a fourfold-or-greater increase in antibody titer, most se-
rologic evaluations for the ehrlichioses and RMSF are based
on analysis of a single acute-phase serum sample (2a, 4). Sec-
ondary testing of whole blood or serum by PCR would have
been required to confirm the diagnosis of HME in all nine of
these patients, as only three or four would have been classified
as probable on the basis of their clinical disease and a single
positive serologic titer (IgM or IgG).
Although results from molecular diagnostic methods corre-
lated well with the culture-positive samples, PCR testing for
HME is not a universally available or necessarily desirable
confirmatory test for routine application. The PCR assays con-
ducted in this study were performed on whole blood, not se-
rum, and in many instances serum or coagulated whole blood
will be the only sample submitted to laboratories. Although
potentially useful in certain applications, serum-based PCR
assays for the human ehrlichioses are still under assessment
(3,- 6, 11, 15). In addition, there remain questions in interpret-
ing a single positive PCR result in the absence of serologic or
other corroborating laboratory results. Culture confirmation of
HME, as with HGE (9), must be regarded as the gold standard
for investigation of the parameters of other diagnostic tests,
although this method may not ultimately be the most sensitive
measure of infection.
The results we present here for HME cases are not unique
among the tick-borne rickettsioses. In analyses comparing cul-
ture-proven and culture-negative cases of HGE, nested PCR
assays for the 16S rDNA showed a concordance of 100% with
eight culture-proven cases, as did detection of morulae for
seven available samples (9). However, at initial presentation,
only two of eight culture-positive cases had antibodies to HGE
antigen that were detectable by IFAs designed to detect mul-
tiple classes of antibody, although six of the eight eventually
showed fourfold-or-greater titer changes at the second sam-
pling. In an additional study of HGE, two of four culture-
positive patients had “equivocal” IgM or IgG titers (1:80) at
the first IFA 2 days after onset of disease (serologically nega-
tive samples from the other culture-confirmed cases were col-
lected 1 and 5 days after disease onset), although enzyme
immunoassay and Western immunoblotting results were neg-
ative for these four culture-positive patients at initial presen-
tation (16). Similarly, approximately half of all fatalities due to
RMSF occur within the first week of illness in persons lacking
diagnostic antibody titers at the time of death. These deaths
would not be classified as even probable RMSF cases without
subsequent autopsy and immunohistochemical demonstration
of rickettsiae in tissues by pathologists (13a).
A survey of state health departments conducted by CDC
indicated that in 1997, ehrlichiosis (HGE and/or HME) was a
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reportable condition in 19 states, of which 13 offered some type
of serologic testing for antibody (12). Of these 13 state labo-
ratories, 7 offered molecular diagnostic testing, although at
least two depended entirely on university or private laborato-
ries for PCR testing. Less than one-third of the states that
mandate ehrlichiosis reporting have the capacity to offer addi-
tional laboratory testing beyond serology, and it seems certain
that despite the recognized limitations, serologic testing will
remain the standard for evaluation of suspected HME cases
into the near future. The current standards and limitations of
laboratory methods for diagnosing HME indicate that if addi-
tional efforts are to be made to improve the sensitivity and
specificity of available diagnostic procedures, then encouraging
the collection of convalescent-phase blood specimens may be
the most reasonable recourse for the immediate future. Addi-
tional efforts among research institutions, state health depart-
ments, and CDC are required to help assess and define the
analytical and diagnostic sensitivities and specificities of the
myriad PCR assays currently in use. When the distinction be-
tween confirmed and probable HME cases is required for
specific studies, arrangements should be made for the collec-
tion of anticoagulated whole blood specimens for confirmatory
testing by PCR or isolation at a site performing these activities.
As a complement to current surveillance efforts, studies that
estimate errors in calculating HME case numbers by using
various laboratory assays and limited specimens will be of
continued importance.
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